TMTom A. Mulder

Tom A. Mulder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tom A. Mulder has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    T‐cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia

    by Maria L. Andersson, Olina Lind, Kia Heimersson, Anna Berglöf, Teresa del Peso Santos, Lucía Peña‐Pérez, Qing Wang, Tom A. Mulder, Rula Zain, Robert Månsson, et al.


  • Open Access

    A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)

    by Wen Zhong, Parviz Kokhaei, Tom A. Mulder, Amineh Ghaderi, Ali Moshfegh, Jeanette Lundin, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, et al.

    Background/Objectives: Nurse-like cells (NLCs) derived from monocytes in the tumor microenvironment support the growth of chronic lymphocytic leukemia (CLL) cells. Here, we investigated the effects of a CX3CR1 (fractalkine receptor) antagonist (KAND567) on autologous monocytes and their pro-survival effects on CLL cells in vitro. Methods: Plasma concentration of CX3CL1 was determined by ELISA and CX3CR1 expression by flow cytometry. CD19+ cells and autologous monocytes from patients with CLL and healthy donors were treated with KAND567 either in co-culture or alone. The apoptosis of CD19+ cells and monocytes was determined by Annexin V/PI staining and live-cell imaging. Results: Plasma concentration of CX3CL1 (fractalkine) was significantly higher in patients with CLL (n = 88) than in healthy donors (n = 32) (p < 0.0001), with higher levels in patients with active compared to non-active disease (p < 0.01). CX3CR1 was found on monocytes but not B cells in patients and controls. Levels of intermediate and non-classical CX3CR1+ monocytes were higher in patients with CLL than in controls (p < 0.001), particularly in those with active disease (p < 0.0001). Co-culture experiments revealed that autologous monocytes promoted the survival of both malignant and normal B cells and that KAND567 selectively inhibited the growth of CLL cells in a dose-dependent manner but only in the presence of autologous monocytes (p < 0.05). Additionally, KAND567 inhibited the transition of monocytes to NLCs in CLL (p < 0.05). Conclusions: Our data suggest that the CX3CR1/CX3CL1 axis is activated in CLL and may contribute to the NLC-driven growth-promoting effects of CLL cells. KAND567, which is in clinical trials in other disorders, should also be explored in CLL.


  • Open Access

    Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?

    by Agnes Mattsson, Jeanette Lundin, Tom A. Mulder, Sandra E. Sylvan, Marzia Palma, Lotta Hansson, Anders Österborg


  • Open Access

    Temporary cessation of ibrutinib results in reduced grade 3‐4 infections and durable remissions—Interim analysis of an on‐off‐repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia

    by Jeanette Lundin, Tom A. Mulder, Magdalena Kättström, Tove Wästerlid, Anders Uddevik, Håkan Mellstedt, Kia Heimersson, Lotta Hansson, Marzia Palma, Anders Österborg

    Ibrutinib is used continuously in CLL. This phase 1b/2 study interim analysis explored on-off-repeat dosing to reduce toxicity. After 12 months, 16/22 patients (73%) remained in first off-phase irrespective if initial CR/PR or TP53 aberration. Grade 3-4 infections were reduced from 55% to 5% during a similarly long off-phase (P < .01). Treg and exhausted T-cells increased (P = .01). Six patients restarted ibrutinib at early progression and remain drug-sensitive. Our interim analysis shows a durable off-phase in most patients, with reduced infections and cost-saving potential. If toxicity-driven permanent cessation of ibrutinib will be affected will be explored in the extended study.


  • Open Access

    Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application

    by Tom A. Mulder, Björn E. Wahlin, Anders Österborg, Marzia Palma

    In lymphomas of B-cell origin, cancer cells orchestrate an inflammatory microenvironment of immune and stromal cells that sustain the tumor cell survival and growth, known as a tumor microenvironment (TME). The features of the TME differ between the different lymphoma types, ranging from extremely inflammatory, such as in Hodgkin lymphoma, to anergic, leading to immune deficiency and susceptibility to infections, such as in chronic lymphocytic leukemia. Understanding the characteristic features of the TME as well as the interactions between cancer and TME cells has given insight into the pathogenesis of most lymphomas and contributed to identify novel therapeutic targets. Here, we summarize the preclinical data that contributed to clarifying the role of the immune cells in the TME of different types of lymphomas of B-cell origin, and explain how the understanding of the biological background has led to new clinical applications. Moreover, we provide an overview of the clinical results of trials that assessed the safety and efficacy of drugs directly targeting TME immune cells in lymphoma patients.


  • Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients

    by Marzia Palma, Lotta Hansson, Tom A. Mulder, Lars Adamson, Barbro Näsman‐Glaser, Ingrid Eriksson, Kia Heimersson, Harriet Ryblom, Fariba Mozaffari, Ann Svensson, et al.

    Objectives: We previously showed that immunization with ex vivo‐ generated autologous dendritic cells loaded with apoptotic tumor cells (Apo‐DC) potentiated tumor‐specific immunity in chronic lymphocytic leukemia (CLL) patients. Here, we evaluated safety and immunogenicity of Apo‐DC in combination with lenalidomide, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), and low‐dose cyclophosphamide (CTX).Methods: Ten previously untreated patients with slowly progressing CLL received 5 Apo‐DC vaccinations and lenalidomide orally for 24 weeks either alone (cohort I, n = 5) or together with subcutaneous GM‐CSF and intravenous CTX (cohort II, n = 5). Tumor‐specific T‐cell responses were measured by proliferation and IFN‐γ ELISPOT assays. Immune monitoring was performed by flow cytometry.Results: Dose‐limiting toxicity was observed in 3/10 patients, 2 in cohort I and one in cohort II. One patient developed autoimmune hemolytic anemia and another grade 4 thrombocytopenia. Vaccine‐induced immune responses were seen in 5/5 and 4/5 patients in cohort I and II, respectively. The expression of immune checkpoints on T cells did not change significantly.Conclusions: Lenalidomide alone or in combination with GM‐CSF and low‐dose CTX as immune adjuvant to the Apo‐DC vaccine elicited tumor‐specific T‐cell responses in CLL patients. However, unexpected toxicity was observed and caution is suggested in further exploring this drug as immune adjuvant in CLL.